Analysts at broker Peel Hunt remain impressed by hVIVO PLC's (AIM:HVO) unique offering in the human challenge trial segment and the rapid diversification of its services.
The broker's view comes in light of hVIVO’s launch of the full suite of its hLAB standalone services, expanding its virology and immunology laboratory offerings.
hVIVO’s new Canary Wharf facility features a new CL-3 laboratory, allowing work with hazard group 3 pathogens.
hLAB has also expanded its assay portfolio to include services for a range of new pathogens, including Omicron, Bordetella pertussis, and various strains of influenza, among others.
“This positions hVIVO as a potential specialised full-service CRO (contract research organisation) of scale,” said Peel Hunt.
“While we do not expect these new services to significantly impact FY24E forecasts, the development of additional contracts and services, such as field challenge trials and hLAB, presents potential upside risk to the mid- to long-term revenue guidance of £100m by 2028.”